Get the Stockscreener App
24.76
2.90%
-0.74
After Hours:
24.90
0.14
+0.57%
Xoma Royalty Corp stock is traded at $24.76, with a volume of 13,916.
It is down -2.90% in the last 24 hours and up +1.56% over the past month.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
See More
Previous Close:
$25.50
Open:
$25.755
24h Volume:
13,916
Relative Volume:
0.43
Market Cap:
$296.38M
Revenue:
$9.71M
Net Income/Loss:
$-29.96M
P/E Ratio:
-7.1149
EPS:
-3.48
Net Cash Flow:
$-14.79M
1W Performance:
-0.36%
1M Performance:
+1.56%
6M Performance:
-25.98%
1Y Performance:
-1.90%
1-Day Range:
$24.63
$25.75
1-Week Range:
$24.50
$27.00
52-Week Range:
$18.35
$35.00
Xoma Royalty Corp Stock (XOMA) Company Profile
Name
Xoma Royalty Corp
Sector
Industry
Phone
510-204-7239
Address
2200 POWELL STREET, EMERYVILLE, CA
Compare XOMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
24.76 | 297.38M | 9.71M | -29.96M | -14.79M | -3.48 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | The Benchmark Company | Buy |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Sep-07-21 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-29-21 | Initiated | Aegis Capital | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-18-18 | Reiterated | H.C. Wainwright | Buy |
| Oct-17-17 | Resumed | H.C. Wainwright | Buy |
| Sep-05-17 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-12-17 | Initiated | H.C. Wainwright | Buy |
| Nov-14-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-16 | Reiterated | Wedbush | Outperform |
| Jul-23-15 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-15 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-22-15 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-10-14 | Resumed | ROTH Capital | Buy |
| Apr-29-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-11-14 | Downgrade | MLV & Co | Buy → Hold |
| Mar-05-14 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-31-13 | Reiterated | MLV & Co | Buy |
| May-09-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-14-12 | Initiated | Cowen & Co | Outperform |
| Mar-31-11 | Reiterated | MLV Capital | Buy |
| Mar-23-11 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-06-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jan-04-11 | Reiterated | Wedbush | Outperform |
View All
Xoma Royalty Corp Stock (XOMA) Latest News
Wall Street Zen Upgrades XOMA (NASDAQ:XOMA) to Buy - Defense World
HC Wainwright Issues Positive Outlook for XOMA Earnings - Defense World
XOMA Co. (NASDAQ:XOMAO) Short Interest Update - Defense World
XOMA Co. (NASDAQ:XOMAP) Short Interest Update - Defense World
XOMA’s (XOMA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
XOMA Royalty purchases mezagitamab royalty rights from BioInvent International for $30M - MSN
XOMA stock holds Buy rating, $104 target from H.C. Wainwright - Investing.com
XOMA stock holds Buy rating, $104 target from H.C. Wainwright By Investing.com - Investing.com South Africa
XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
XOMA Stock: HC Wainwright & Co. Reiterates Buy Rating with $104 - GuruFocus
XOMA Purchases Future Mezagitamab Royalty Interests from BioInve - GuruFocus
XOMA Royalty (XOMA) Acquires Mezagitamab Interests from BioInvent - GuruFocus
XOMA Royalty Purchases Mezagitamab Royalty and Milestone - GlobeNewswire
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million - Yahoo Finance
Northern Trust Corp Has $2.40 Million Holdings in XOMA Co. (NASDAQ:XOMA) - Defense World
XOMA (NASDAQ:XOMAO) Stock Price Up 0.1% – Still a Buy? - Defense World
XOMA (NASDAQ:XOMAP) Trading Up 1.5% – Still a Buy? - Defense World
Major Shareholder Sells Massive Chunk of Xoma Stock! - TipRanks
Leerink Partnrs Analysts Boost Earnings Estimates for XOMA - Defense World
FY2026 Earnings Estimate for XOMA Issued By Leerink Partnrs - Defense World
Results: XOMA Royalty Corporation Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
XOMA Royalty First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
XOMA Royalty Reports Strong Q1 2025 Results - TipRanks
XOMA Royalty Corp Q1 2025 Earnings: EPS of $0.24, Revenue Surges to $15.9 Million, Exceeding Estimates - GuruFocus
XOMA (XOMA) Surpasses Q1 Revenue Expectations with Strong Pipeli - GuruFocus
XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
XOMA Royalty Corporation Q1 2025 Financial Results - TradingView
XOMA Royalty Corp SEC 10-Q Report - TradingView
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements - The Manila Times
Wells Fargo & Company MN Grows Stock Holdings in XOMA Co. (NASDAQ:XOMA) - Defense World
Barclays PLC Acquires 1,528 Shares of XOMA Co. (NASDAQ:XOMA) - Defense World
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference - GlobeNewswire
XOMA Royalty Corp expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Buys 7,619 Shares of XOMA Co. (NASDAQ:XOMA) - Defense World
JPMorgan Chase & Co. Raises Stake in XOMA Co. (NASDAQ:XOMA) - Defense World
XOMA Co. (NASDAQ:XOMAO) Sees Significant Increase in Short Interest - Defense World
XOMA Co. (NASDAQ:XOMA) Shares Sold by Geode Capital Management LLC - Defense World
Short Interest in XOMA Co. (NASDAQ:XOMAP) Drops By 15.9% - Defense World
Benchmark Begins Coverage on XOMA (NASDAQ:XOMA) - Defense World
Benchmark Initiates Coverage of XOMA Royalty CorporationPreferred Stock (XOMAP) with Buy Recommendation - Nasdaq
Benchmark Initiates Coverage of XOMA Royalty (XOMA) with Buy Recommendation - Nasdaq
XOMA Co. (NASDAQ:XOMAO) Sees Large Decrease in Short Interest - Defense World
Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals
Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals
XOMA Royalty Corporation's (NASDAQ:XOMA) Path To Profitability - Yahoo
XOMA completes sale of Kinnate assets for up to $270 million - Investing.com Australia
Xoma Royalty Completes Sale Of Kinnate Pipeline Assets - MarketScreener
XOMA Royalty Completes Sale of Kinnate Pipeline Assets - The Manila Times
XOMA Co. (NASDAQ:XOMA) Director Joseph M. Limber Buys 17,935 Shares - MarketBeat
XOMA (NASDAQ:XOMA) Stock Rating Upgraded by StockNews.com - Defense World
XOMA Royalty Corp's chief investment officer purchases $49,400 in depositary shares By Investing.com - Investing.com India
Xoma Royalty Corp Stock (XOMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):